miR-451a Inhibits the Growth and Invasion of Osteosarcoma via Targeting TRIM66

Xiao Ma, MD1, Dan Li, BS1, Yan Gao, BS1, and Cheng Liu, BS1

Abstract
The importance of microRNAs in regulating osteosarcoma development has been studied in recent years. However, the function of microRNA-451a in osteosarcoma growth is rarely investigated. Here, we explored the expression of microRNA-451a in osteosarcoma cell lines. Bioinformatic software, luciferase activity reporter assay, and Western blot were conducted to determine the association between microRNA-451a and tripartite motif-containing 66. Cell Counting Kit-8 assay and transwell assay were used to explore the regulatory effects of microRNA-451a on osteosarcoma cells. Moreover, we explored whether microRNA-451a modulates osteosarcoma cell biological activity by regulating tripartite motif-containing 66. The expression of microRNA-451a was found to be downregulated in osteosarcoma and negatively regulated the expression of tripartite motif-containing 66. Tripartite motif-containing 66 was further validated as a target of microRNA-451a. MicroRNA-451a inhibits the growth and invasion of osteosarcoma cell lines through targeting tripartite motif-containing 66. The miR-451a targets tripartite motif-containing 66 may provide novel therapeutic targets for the treatment of osteosarcoma.

Keywords
miR-451a, TRIM66, osteosarcoma, proliferation, invasion

Abbreviations
CCK-8, Cell Counting Kit-8; DMEM, Dulbecco modified Eagle medium; FBS, fetal bovine serum; miR-451a, microRNA-451a; mt, mutant; NC mimic, negative control miRNA for mimic; OS, osteosarcoma; pTRIM66, pcDNA3.1 containing the open reading frame of TRIM66; qRT-PCR, quantitative real-time polymerase chain reaction; TRIM66, tripartite motif-containing 66; UTR, untranslated region; wt, wild-type.

Received: March 24, 2019; Revised: May 11, 2019; Accepted: June 14, 2019.

Introduction
Osteosarcoma (OS) is a common cancer type that represents approximately half of all bone cancers worldwide.1 The 5-year overall survival of patients with OS has been elevated to about 60% due to the improvements in chemotherapy or surgical resection.2 However, the overall survival of patients with OS diagnosed at late stages or metastasis remains undesirable.3 Therefore, investigating the molecules that contribute to the progression of OS is essential for the discovery of novel therapeutic methods.

MicroRNAs (miRNAs) are endogenous RNAs that have been found to be able to modulate target gene expression through 3’-untranslated region (3’-UTR) binding.4 Multiple miRNAs have been reported to function crucial roles in regulating OS progression.5 MicroRNA-451a (miRNA-451a) is an miRNA that reported to be a tumor suppressor in certain human cancers.6,8 For instance, miR-451a was found to be downregulated in colorectal cancer tissues and cells.6 Moreover, it was found that overexpression of miR-451a was able to inhibit colorectal cancer progression in vitro by BAP31 5’-UTR binding.6 In addition, miR-451a was revealed to be downregulated in non-small cell lung cancer and its overexpression inhibits cell proliferation and metastasis via targeting activating transcription factor 2.7 Besides that, overexpression of miR-451a arrested cutaneous basal cell

1 Department of Orthopedics, New District, Hohhot, People’s Republic of China

Corresponding Author:
Cheng Liu, Department of Orthopedics, No. 969 Hospital of the Joint Logistic Support Force, 57 Aimin Street, New District, Hohhot 010051, People’s Republic of China.
Email: dr_liucheng@126.com
carcinoma cell cycle at G1 phase via regulating the expression of TBX1 to function as tumor suppressor. All these evidence pointed out the importance of miR-451a in regulating cancer tumorigenesis. Despite all of that, the exact role of miR-451a in regulating OS progression was investigated.

Tripartite motif-containing 66 (TRIM66), a member of TRIM-containing proteins, with its role in human cancer is not fully understood. In non-small cell lung cancer, it was demonstrated that TRIM66 silencing suppressed cancer malignant behaviors. Furthermore, high TRIM66 expression was found to be correlated with lymph node metastasis, advance Tumor Node Metastasis (TNM) stage, and poor overall survival of patients with non-small cell lung cancer. As to OS, TRIM66 was reported to function as an oncogene and correlated with poor survival outcome of patients with cancer. However, the molecules that can regulate TRIM66 expression was rarely investigated.

In this study, we explored the expression of miR-451a and TRIM66 in OS cell lines and the normal cell line. Connection between miR-451a and TRIM66 was investigated by luciferase activity reporter assay and Western blot assay. Effects of miR-451a or TRIM66 expression on OS cell proliferation and invasion were analyzed with Cell Counting Kit-8 (CCK-8) assay and transwell invasion assay, respectively.

Materials and Methods

Cell Lines and Transfection
Osteosarcoma cell lines (Saos-2, U2OS, and MG63) and normal osteoblasts (hFOB 1.19) purchased at American Type Culture Collection (Manassas, Virginia) were maintained in Dulbecco modified Eagle medium (DMEM; Invitrogen, Thermo Fisher Scientific, Inc, Waltham, Massachusetts) with 10% fetal bovine serum (FBS, Invitrogen) in a 37°C humidified incubator containing 5% CO2 and 95% air.

MicroRNA-451a mimic (5'-AACCGUUACCUAAUCAGU-3') and negative control (negative control miRNA for mimic [NC] mimic; 5'-AUCUGAACCGGAAUUUAC-3') were purchased at GenePharma (Shanghai, China). The pcDNA3.1 containing the open reading frame of TRIM66 (pTRIM66) was generated by GenScript (Nanjing, China). Cell transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Quantitative Real-Time Polymerase Chain Reaction
The RNA sample of the cultured cells was isolated using TRIzol (Invitrogen). Complementary deoxyribonucleic acid was synthesized from the extracted RNA using Primerscript RT Reagent (Takara, Dalian, China). Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted on ABI 7500 equipment (Applied Biosystems, Foster City, California) using SYBR Green Mix (Takara) with the following primers: miR-451a, F: 5'-ACACTCCAGCTGGGAAACCGTTAC-CATTAC-3'; R: 5'-CTCAACTGTTCTGACCTGAGTCC-GCAATTCAGTTGAGCTTAC-3' and U6 small nuclear RNA (U6 snRNA), F: 5'-CTCGTTTGCGACTC-3'; R: 5'-AACGTTACGGAATTTTGCG-3'. The following procedures were used: 1 cycle at 95°C for 2 minutes, 40 cycles at 95°C for 30 seconds, and 58°C for 40 seconds. Relative expression level of miR-451a was analyzed with the 2−ΔΔCt method.

Western Blot
Protein sample of the cultured cells was isolated using radioimmunoprecipitation assay lysis buffer (Beyotime, Haimen, Jiangsu, China). After quantified with bicinchoninic acid protein concentration determination kit (Beyotime), equal amount of protein sample was isolated at 10% sodium lauryl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane. The membrane was blocked with fat-free milk, incubated with primary antibodies at 4°C for overnight and secondary antibody at 37°C for 4 hours. Band signals were developed using BeyoECL kit (Beyotime) and analyzed using the Image J version 1.42 software (National Institutes of Health, Bethesda, Maryland). The antibodies used in this work were anti-TRIM66: ab108445, anti-matrix metallopeptidase 9 (MMP-9): an73734, anti-glyceraldehyde 3-phosphate dehydrogenase: ab181602, and horseradish peroxidase conjugated goat antirabbit secondary antibody: ab6721; all were purchased from Abcam, Cambridge, Massachusetts.

CCK-8 Assay
Proliferation rate of OS cell lines was analyzed with CCK-8 assay (Beyotime). Cells at the density of 2 × 10^3 cells/well were seeded into 96-well plates and maintained at the above-mentioned conditions. Subsequently, 10 µL of CCK-8 reagent was added to each well at indicated time point. After further incubation for 4 hours, absorbance of each well was measured at 450 nm using a microplate reader.

Transwell Assays
Invasion ability of OS cell lines was analyzed with transwell invasion assay. The chamber (Corning, Corning, New York) was precoated with Matrigel (BD Biosciences, San Jose, California); 3 × 10^4 cells in serum-free DMEM were added in the upper chamber, while the DMEM containing 10% FBS was added to the lower chamber. After 48 hours of incubation, invasive cells were fixed with methanol, stained with crystal violet, and counted under a light microscope.

Dual-Luciferase Reporter Gene Assay
Bioinformatic algorithms (http://www.targetscan.org/vert_72/) predicted that TRIM66 was a potential target of miR-451a. The wild-type 3'-UTR of TRIM66 was cloned from genome and inserted into pMIR-REPORT (Promega, Madison, Wisconsin) and named as wt-TRIM66. The mutant type of 3'-UTR of TRIM66 (mt-TRIM66) was built from wt-TRIM66 using site-direct mutagenesis kit (Takara). Cells were cotransfected with wt-TRIM66 or mt-TRIM66 and miR-451a mimic or NC
mimic using Lipofectamine 2000. After 48 hours of transfection, relative luciferase activity was analyzed using Dual-luciferase Reporter Assay System (Promega).

**Statistical Analyses**

GraphPad Prism version 6.0 software (GraphPad, Inc, La Jolla, California) was used for statistical analysis. Data were presented as mean (standard deviation). Student t test or analysis of variance with Tukey post hoc test were used for analyzing the differences in groups. P < .05 was indicated as significant difference.

**Results**

**Expression of miR-451a and TRIM66 in OS Cell Lines**

To assess the expression pattern of miR-451a in OS, we analyzed the expression of miR-451a in OS cell lines and normal cell line using qRT-PCR. As indicated in Figure 1A, we found miR-451a was significantly decreased in OS cell lines compared with the normal cell line. In addition, we showed TRIM66 expression was significantly elevated in OS cell lines compared to the normal cell line (Figure 1B). Based on these analyses results, U2OS and MG63 were selected for following analyses.

**miR-451a Could Regulate TRIM66 Expression by 3’-UTR Binding**

Bioinformation algorithms were used to predict the targets of miR-451a. As presented in Figure 2A, TRIM66 contains a binding site for miR-451a in its 3’-UTR. In addition, we found the transfection of miR-451a mimic could significantly increase the levels of miR-451a in OS cell lines (Figure 2B). Luciferase reporter assay revealed that luciferase activity of cells transfected with wt-TRIM66 could be reduced by miR-451a mimic, indicating the direct interaction between miR-451a and the 3’-UTR of TRIM66 (Figure 2C). Furthermore, Western blot assay revealed that TRIM66 protein expression level could be reduced by miR-451a mimic (Figure 2D). These results indicated that TRIM66 was a direct target of miR-451a.

**MicroRNA-451a Inhibits OS Cell Proliferation and Invasion Through Targeting TRIM66**

The CCK-8 assay and transwell invasion assay were conducted to analyze the role of miR-451a on OS cell proliferation and invasion. Results of CCK-8 assay showed that overexpression of miR-451a significantly suppressed the proliferation rate of OS cells compared with NC mimic (Figure 3A). Moreover, transwell invasion assay indicated that miR-451a mimic decreased cell invasion ability (Figure 3B). To investigate whether the tumor-suppressive role of miR-451a was exerted through TRIM66, miR-451a mimic, and pTRIM66 were cotransfected into OS cells. We found TRIM66 expression level was increased by pTRIM66 (Figure 3C). As to the biological roles of TRIM66, we found TRIM66 overexpression enhanced the proliferation and invasion of OS cells (Figure 3A and B). Furthermore, we showed the suppression effects of miR-451a on OS cell behaviors could be partially reversed by pTRIM66 (Figure 3C). By detecting the expression of MMP-9 in these groups, we found TRIM66 expression was enhanced by pTRIM66 but reduced by miR-451a mimic (Figure 3D). These results indicated that miR-451a suppresses OS cell proliferation and invasion through regulating TRIM66.

**Discussion**

The clinical outcome of patients with OS did not significantly improve in the past 30 years partially due to the biological
complexity of this tumor type.\textsuperscript{13,14} Therefore, it is imperative to explore the abnormal expressed genes associated with the progression of OS. In recent years, the importance of miRNAs in regulating OS progression has been concerned. For instance, miR-758 was identified to be downregulated in OS and correlated with poor overall survival of patients with OS.\textsuperscript{15} In addition, the overexpression of miR-758 was shown to inhibit the malignant features of OS cells \textit{in vitro}.\textsuperscript{15} Furthermore, it was found miR-1258 overexpression inhibited OS cell proliferation through arrested cell cycle at G0/G1 phase.\textsuperscript{16}

In this current work, we demonstrated that miR-451a expression was reduced in OS cell lines compared to the normal cell line. Furthermore, functional assays revealed that overexpression of miR-451a by miR-451a mimic inhibited OS cell proliferation and invasion \textit{in vitro}. These results collectively indicated that miR-451a may function as a tumor suppressor in the progression of OS, which is inconsistent with its role in cancers including colorectal cancer, non-small cell lung cancer, and cutaneous basal cell carcinoma.\textsuperscript{6-8}

Considering that each miRNA can regulate multiple target genes and several targets of miR-451a have been identified in previous studies,\textsuperscript{6-8} we are interested to investigate the target of miR-451a in OS to understand the role of miR-451a. By bioinformatic analyses, we showed TRIM66, an oncogene in several cancer types,\textsuperscript{10-12} contains a putative binding site in its 3\'-UTR. Luciferase activity reporter assay and Western blot assay were conducted to validate this prediction result. We showed that miR-451a mimic transfection could downregulate the

---

**Figure 2.** Tripartite motif-containing 66 was a direct target of miR-451a. A, Putative binding model between TRIM66 3\'UTR and miR-451a. B, MicroRNA-451a expression in OS cells with synthetic miRNA transfection. C, Luciferase activity in OS cells transfected with wt-TRIM66 or mt-TRIM66 and synthetic miRNAs. D, Tripartite motif-containing 66 expression in OS cells with synthetic miRNA transfection. ***\textit{P} < .001, **\textit{P} < .01, *\textit{P} < .05. miR-451a indicates microRNA-451a; mt, mutant; NC mimic, negative control miRNA for mimic; OS, osteosarcoma; TRIM66, tripartite motif-containing 66; UTR, untranslated region; wt, wild-type.
luciferase activity of cells transfected with wt-TRIM66, indicating the interaction between miR-451a and TRIM66 3'UTR. Western blot showed TRIM66 could be negatively regulated by miR-451a in OS cells. Functional assays revealed that TRIM66 overexpression could promote the malignant behaviors of OS cells and partially reversed the effects of miR-451a. Primary OS cell cultures obtained from patients with cancer displayed different proliferation kinetics and osteoid production with the commercial cell lines. Therefore, the usage of primary OS cell culture is necessary to validate the conclusions of our work in the future.

Figure 3. MicroRNA-451a inhibits OS cell proliferation and invasion through targeting TRIM66. A, Cell proliferation. B, Cell invasion. C, TRIM66 expression. D, MMP-9 expression in OS cells transfected with miR-451a mimic, NC mimic, pTRIM66, pcDNA3.1, or miR-451a mimic and pTRIM66. ***P < .001, **P < .01, *P < .05. MMP-9 indicates matrix metallopeptidase 9; miR-451a, microRNA-451a; NC mimic, negative control miRNA for mimic; OS, osteosarcoma; TRIM66, tripartite motif-containing 66.
In conclusion, expression of miR-451a was found to be reduced in OS cells. Furthermore, miR-451a suppressed the growth and invasion of OS cells in vitro by directly targeting TRIM66. Investigation of the roles of miR-451a in OS was helpful to understand the mechanism related to OS tumorigenesis and will be beneficial for novel treatment measures development.

Authors’ Note
Written informed consent was obtained from all individuals who participated in the study. Our study did not require an ethical board approval because it did not contain human or animal trials.

Declaration of Conflicting Interests
The author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Cheng Liu https://orcid.org/0000-0002-1185-1172

References
1. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol. 2014;16:15-23.
2. Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: an updated review. Indian J Med Paediatr Oncol. 2017;38(1):33-43.
3. Eleuterio SJ, Senerchia AA, Almeida MT, et al. Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults. Pediatr Blood Cancer. 2015;62(7):1209-1213.
4. Bartel DP. microRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
5. Wang M, Xie R, Si H, Shen B. Integrated bioinformatics analysis of miRNA expression in osteosarcoma. Artif Cells Nanomed Biotechnol. 2017;45(5):936-943.
6. Xu K, Han B, Bai Y, et al. MiR-451a suppressing BAP31 can inhibit proliferation and increase apoptosis through inducing ER stress in colorectal cancer. Cell Death Dis. 2019;10(3):152.
7. Shen YY, Cui JY, Yuan J, Wang X. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci. 2018;22(17):5554-5561.
8. Sun H, Jiang P. MicroRNA-451a acts as tumor suppressor in cutaneous basal cell carcinoma. Mol Genet Genomic Med. 2018;6(6):1001-1009.
9. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792-804.
10. Dai HY, Ma Y, Da Z, Hou XM. Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer. Pathol Res Pract. 2018;214(8):1130-1135.
11. Ma Y, Dai HY, Zhang F, Zhao D. TRIM66 expression in non-small cell lung cancer: a new predictor of prognosis. Cancer Biomark. 2017;20(3):309-315.
12. Chen Y, Guo Y, Yang H, et al. TRIM66 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. Oncotarget. 2015;6(27):23708-23719.
13. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65-92.
14. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1-2):247-263.
15. Ren J, Yang M, Xu F, Chen J. microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting HMGAI and deactivating the Wnt/β-catenin pathway. Am J Cancer Res. 2019;9(1):36-52.
16. Liu W, Zhou Z, Zhang Q, et al. Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma. Biochem Biophys Res Commun. 2019;510(3):479-486.
17. Laschi M, Bernardini G, Geminiani M, et al. Establishment of four new human primary cell cultures from chemo-naïve Italian osteosarcoma patients. J Cell Physiol. 2015;230(11):2718-2727.
18. Laschi M, Bernardini G, Geminiani M, et al. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor. Biofactors. 2017;43(6):801-811.